The Food and Drug Administration today released draft guidance for assessing risk evaluation and mitigation strategies. FDA may require a REMS before approving certain drugs, including biologics, to help ensure its benefits outweigh its risks. FDA Commissioner Scott Gottlieb, M.D., said the guidance provides a framework for companies to develop an assessment plan when they develop a REMS program to improve the quality of the information used to assess the program’s effectiveness and provide post-market evidence that the REMS is meeting its risk mitigation goals. “We need to make sure that the REMS are achieving their public health goals, and that we’re designing and implementing these approaches in ways that minimize burdens to patients and providers,” he said.

Related News Articles

Headline
AHA yesterday voiced support for the National Coronavirus Commission Act (S. 412), legislation that would create a national commission to examine lessons…
Headline
During an AHA virtual briefing for lawmakers and staff, leaders from three health systems — One Brooklyn Health System, Grady Health System, and The Hospitals…
Headline
Strategic alliances forged by AHA with organizations like the National Urban League and UnidosUS are strengthening collective effort to address well-documented…
Blog
Nearly 55 years ago, during the 1966 Medical Committee of Human Rights Convention, the Rev. Dr. Martin Luther King Jr. declared, “Of all the forms of…
Chairperson's File
Join me on this episode of Leadership Rounds with Consuelo Wilkins, M.D., vice president of health equity at Vanderbilt University Medical Center, based in…
Headline
The AHA recently launched a new webpage dedicated to disseminating accessible information focused on addressing the equity issues in COVID-19 testing,…